U.S. Markets closed

Roche Holding AG (RHO6.DE)


XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
29.0650.00 (0.00%)
At close: 4:09PM CEST
People also watch
RHO5.DERHO.DENOT.DE
Full screen
Previous Close29.065
Open29.065
Bid0.000 x 15000
Ask0.000 x 880700
Day's Range29.065 - 29.065
52 Week Range25.600 - 31.225
Volume600
Avg. Volume18
Market Cap196.74B
BetaN/A
PE Ratio (TTM)20.32
EPS (TTM)1.43
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks9 hours ago

    Roche's (RHHBY) Combination Cancer Remedy Wins FDA Approval

    Roche (RHHBY) announced that the FDA has granted approval to the subcutaneous injection of its marketed lymphoma drug MabThera/Rituxan as Rituxan Hycela for the treatment of adults with different types of blood cancers.

  • Reuters13 hours ago

    New Roche haemophilia drug prevents bleeds but questions remain

    Roche's investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients with resistance to standard therapy compared with those who received another treatment, the Swiss company said on Monday. Roche is counting on emicizumab to wrest a share of the $11 billion-a-year haemophilia drug market now dominated by traditional treatments from Novo Nordisk and Shire . Some analysts called Monday's data release convincing, with Jefferies saying it underpinned its $5 billion peak sales estimate for the medicine.

  • Reuters15 hours ago

    Roche says new haemophilia drug cuts bleed rate by 87 pct

    Roche's investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients who had developed resistance to standard treatment, compared with those who instead got bypassing agents, the Swiss company said on Monday. Roche is counting on emicizumab to wrest a share of the $11 billion-a-year haemophilia drug market now dominated by traditional treatments from Novo Nordisk and Shire . In the late-stage study, 62.9 percent of patients receiving emicizumab experienced zero treated bleeds compared to 5.6 percent of those receiving so-called bypassing agents, Roche said.